Aripiprazole in autism spectrum disorders and fragile X syndrome. - Wikidata - awgldk - TriplyDB

Aripiprazole in autism spectrum disorders and fragile X syndrome.

Aripiprazole in autism spectrum disorders and fragile X syndrome.

http://www.wikidata.org/entity/Q34025492

about

Aripiprazole for autism spectrum disorders (ASD)Aripiprazole for autism spectrum disorders (ASD)Aggression in autism spectrum disorder: presentation and treatment options Aripiprazole for treating irritability in children & adolescents with autism: A systematic review Fragile X syndrome and targeted treatment trials.Unstable mutations in the FMR1 gene and the phenotypes Reward processing in autism: a thematic series.Potential therapeutic interventions for fragile X syndrome The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.A fourth case of Feingold syndrome type 2: psychiatric presentation and management.Targeted treatments for fragile X syndrome.A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.Aripiprazole for the treatment of irritability associated with autism.Review of the pharmacotherapy of irritability of autism.Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.Lurasidone for the treatment of irritability and anger in autism spectrum disorders.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole.A prospective open-label study of aripiprazole in fragile X syndrome.Fragile X syndrome Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

P2860

Q24197830-EF7FBA2B-F9BC-4577-A7D6-EC0E56433B74 Q26471439-8C30F3E3-00D8-4AF6-8F25-8E4FDFD76087 Q26744346-FA578B61-A1CC-4028-9386-914781826D29 Q26784199-EEDFF635-C5A4-4568-B914-4206462E438A Q26865162-76E0F465-6181-4BE2-99CC-992DB5F40EAC Q26996649-790BD557-568A-4A36-A8FF-61CEE9C4DEC2 Q30462673-4F83C435-0CEB-4B7A-A461-7DB1DA6D4E82 Q30473378-2B7BC59F-9612-4E00-ACEE-28D590081CFA Q34213731-DB9C40BC-07CA-4392-A6F0-3CAFF32604E6 Q34573267-6E355E78-AE95-4999-A4B4-47C6589F5712 Q35680726-7504E185-3457-45B8-8C3E-58E5DC0A1F97 Q36157807-962DCA0A-08DD-40ED-96FE-C234E9EE40AF Q37835845-2B26EF47-C651-41F1-B43B-C8360CA15702 Q38006705-D89C8B52-349C-49F6-A971-8A2D4BDF921E Q38012453-0D2F4959-406B-440F-A2C0-80552F7C7217 Q38095762-2F5AC9E4-94DE-46B3-A90E-23BA73371562 Q38621496-93EE706C-9F75-4F60-9788-C1822A2CC478 Q38689883-FB1DE947-CD9B-4FEA-B6AB-949732A08AFF Q38726962-45068EDF-E664-4D31-B984-F21D1262EE7D Q39162868-0364AAEC-3816-4ED0-BF20-9F8E2428CC28 Q41828115-24CF782A-0A42-4926-A9D9-D6D4F7904574 Q47293259-6CFBC8AA-0494-41A7-8855-01DEF957D08B Q57828399-2D6CA8C5-D2BF-4D3B-944F-69D1989B2156 Q59292055-E7E5AA03-5EC8-41DC-A38B-5B7B407838BC

P2860

Aripiprazole in autism spectrum disorders and fragile X syndrome.

http://www.wikidata.org/entity/Q34025492

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@ast

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@en

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@nl

type

label

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@ast

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@en

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@nl

prefLabel

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@ast

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@en

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@nl

P1433

Q34025492-EC74E2AE-50C2-42AC-A878-2E721F1A2F4C

P1476

Q34025492-8CEA806E-ADA3-4678-9830-677A3FA342D4

P2093

Q34025492-37ECE9FB-0852-4118-B6D1-FF076F70A737

Q34025492-3A16D160-0F82-4488-86F5-A8AC8F901DCA

Q34025492-6B750061-1DAC-4BCB-8219-7062AA33D408

P2860

Q34025492-16FBE057-C518-4BAF-8368-AE01894D1EE8

Q34025492-18AB3D3E-AFB4-401D-87DA-E8DDC3AF2F1A

Q34025492-1DED237F-3150-483E-AF04-11B55BFC15E8

Q34025492-1EBC55B4-BA57-41F4-BBC1-0DC9F9F27257

Q34025492-3B2654CD-FF44-4AE2-9E3C-0F933DBBE063

Q34025492-4745E3C4-9268-4A4B-8D0B-00AA297DC56B

Q34025492-4C63E188-6694-4F4D-B31A-365F0D26F0C4

Q34025492-50DD967D-1076-4A46-B182-D2DBE0DA7FAF

Q34025492-51566439-76B7-41CE-A420-BBA049078F9D

Q34025492-5602CB0F-48FC-4ACA-860D-13D69DD4885A

P2888

Q34025492-2B602D4F-785F-4817-82C7-D34B4838A2AF

P304

Q34025492-E090F51E-691C-4AFF-8A30-4360FEDEB1D6

P31

Q34025492-32AE8DA5-37D3-42B3-9B2C-C63AB8261BF1

P356

Q34025492-31D18DC2-9B60-40DC-90BA-CD24415A986D

P433

Q34025492-09818C11-B7C8-4623-8332-EABBC169AEE1

P478

Q34025492-6A8CA828-728E-4D72-A939-AB81C5BE4D5F

P50

Q34025492-32484B6D-68A7-48E1-B48C-7CD93E55475D

P577

Q34025492-19725D59-5753-4B7B-985F-A9A761FCD406

P5875

Q34025492-48E2CD2E-1333-490D-A967-DCC43F9EC385

P6179

Q34025492-FD848839-6647-42C3-AB2A-493F19B61F15

P698

Q34025492-A1B7509C-7DF6-494A-8417-8A4EE2C77286

P921

Q34025492-02C679DC-0621-48C9-B9E4-4EE6D7F40A8A

Q34025492-F0B28B75-A56B-4DDC-8110-85E26E90222F

P932

Q34025492-63E275C6-E933-4E55-8EB2-DC6BDA468CD1

P356

J.NURT.2010.04.001

P1433

Neurotherapeutics

P1476

Aripiprazole in autism spectrum disorders and fragile X syndrome.

@en

P2093

Craig A Erickson

http://www.w3.org/2001/XMLSchema#string

David J Posey

http://www.w3.org/2001/XMLSchema#string

Kimberly A Stigler

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in the treatment of fragile X syndrome

Pharmacologic treatment of autism and related disorders

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Risperidone in children with autism and serious behavioral problems.

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.

P2888

j.nurt.2010.04.001

P304

258-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NURT.2010.04.001

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J McDougle

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45274547

http://www.w3.org/2001/XMLSchema#string

P6179

1040149961

http://www.w3.org/2001/XMLSchema#string

P698

20643378

http://www.w3.org/2001/XMLSchema#string

P921

Autism spectrum

P932

2911359

http://www.w3.org/2001/XMLSchema#string